• Publications
  • Influence
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.
First-course docetaxel PK is a predictor of first-course hematologic toxicity, but also of fluid retention, which is cumulative in nature.
Pharmacokinetic and pharmacodynamic properties of docetaxel: results of phase I and phase II trials.
Docetaxel pharmacokinetics and pharmacodynamics determined in Phase I and Phase II trials indicate a need to adjust the dosage for body surface area and liver function.
The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication.
Specific investigations for fluid retention confirmed a relationship between cumulative docetaxel dose and development of fluid retention, and a vascular protector such as micronized diosmine hesperidine with recommended corticosteroid premedication and benzopyrones may be useful in preventing and treating docetAXel-induced fluid retention.
A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors
MK-5108 MT was well tolerated at doses up to 3600 mg/day with plasma levels exceeding the minimum daily exposure target (83 μM*hr) and use of pharmacodynamic gene expression assays to determine target engagement was validated.